CATS WITH CHRONIC KIDNEY DISEASE & HEALTHY CATS
The Small Animal Internal Medicine Service is recruiting cats for a study of oxidative stress in early kidney disease. Healthy cats and cats with stage 1 chronic kidney disease (CKD) may qualify for this study.
They will screen apparently healthy cats 6 years of age or older for the study. Cats will have free testing for early kidney disease (urine specific gravity and serum SDMA). Cats with normal kidney function or evidence of early kidney disease will be eligible for the full study and will receive free blood work (CBC, chemistry panel, urinalysis and serum T4). This study will measure blood and urine levels of an oxidative stress (free radical damage) marker called isoprostane. Cats with early kidney disease will be eligible for part two of the study, which will recheck isoprostanes after a month on a defined diet.
Cats with more advanced kidney disease or cats with other diseases (such as inflammatory bowel disease or hyperthyroidism) are not eligible to participate in this study. There is no cost to participate in the study and all tests are done at no charge. Results of routine screening lab tests will be provided to the cat’s primary care veterinarian.
The Small Animal Internal Medicine Service is recruiting Boxer Dogs for a lymphoma study.
Lymphoma is a fatal cancer of the blood cells of dogs. Lymphoma is more common in Boxers, Golden Retrievers and several other purebreds, which suggest involvement of inherited genes. Research shows mutations in the tumors of dogs with lymphoma, but it is unclear why some of these mutations develop or persist in certain dogs. Better understanding of this process may lead to lymphoma prevention.
Canine lymphoma resembles Non-Hodgkin lymphoma (NHL) in people. Non-Hodgkin lymphoma is associated with chemicals found in tobacco smoke, certain household products and pesticides. Glutathione-S-transferase (GST) enzymes break down toxic chemicals in the body and can prevent these chemicals from causing tumor mutations. Because of this, low activity variants of GST enzymes increase the risk of developing NHL.
This study will look for low activity variants in GST genes, which may put boxer dogs at higher risk for lymphoma. In addition, environmental exposures will be assessed by a questionnaire, and the presence of DNA damage will be assessed from a small blood sample.
Any Boxer Dog, with or without lymphoma, may qualify for the study. The inside of the patient’s cheek is swabbed to obtain a DNA sample for GST gene sequencing. The client completes a 5-page questionnaire about the dog’s environment. This may be done at the UW Veterinary Care or at the dog’s primary care veterinarian. In some dogs, a small blood sample will be collected for DNA testing.
Dogs with Bladder Tumors
The Small Animal Internal Medicine and Oncology Services are recruiting patients with bladder tumors. They are interested in whether certain gene defects, in addition to exposure to certain environmental chemicals, contribute to the risk of bladder cancer in dogs.
They are looking to obtain cheek swab samples from dogs of any breed diagnosed with bladder cancer. In addition, we have an environmental exposure questionnaire for dog owners to fill out.
Eligibility: Any dog diagnosed with transitional cell carcinoma of the bladder or urethra. Dogs can be enrolled at any time after diagnosis and may be on any treatment protocol. The inside of the dog’s cheek will be swabbed with a special brush for DNA collection (kit with brushes, instructions, owner questionnaire, and free mailing provided). The swabs and environmental questionnaire will be processed by Dr. Lauren Trepanier‘s laboratory. Please contact Katherine Luethcke, DVM/PhD student at 608-263-5520 or firstname.lastname@example.org with any questions or to obtain a DNA sampling kit.
Dogs with Immune-mediated Hemolytic anemia and Immune-Mediated thrombocytopenia
The Small Animal Internal Medicine Service is recruiting dogs with newly diagnosed (untreated) immune-mediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (ITP). To help in understand why dogs become ill from these conditions and to develop new therapies, investigators will determine the percentages of different blood cells
Both IMHA and ITP can result in life threatening bleeding and anemia IMHA and ITP have high rates of mortality and relapse in dogs. Treatment of these diseases involves the administration of immunosuppressive medications, which can be lifesaving. However, these drugs may be costly and can cause potentially life threatening side effects. More specifically, safer treatments are necessary. In humans, changes in the number or function of a type of immune cell, the B regulatory cell (Breg), have been identified as a possible contributor to the development of these diseases.
The investigators will compare regulatory B cell content, phenotype and IL-10 function between dogs with IMHA and ITP versus healthy dogs. Results of this study will expand knowledge of the causes of these diseases in dogs and serve as the initial groundwork for the administration of B regulatory cells to treat IMHA and ITP both in dogs and humans.
Eligibility: Any dog with newly diagnosed (untreated) primary Immune-Mediated Hemolytic Anemia or primary Immune-Mediated Thrombocytopenia may qualify. Blood are collected throughout the dog’s treatment.
Dogs with Pneumonia
The Small Animal Internal Medicine Service is recruiting dogs with aspiration pneumonia to determine if a marker in the blood helps to determine when to stop treating the patient with antibiotics.
Canine aspiration (bacterial) pneumonia is a common condition that is treated with antibiotics. The length of antibiotic treatment in these cases is a challenge as no consensus has been reached for the ideal length of therapy. A measurable marker could aid in determining the needed duration of treatment with antibiotics. In human medicine, 5-7 days of antibiotics, based on clinical markers, are recommended for patients with bacterial pneumonia. C-Reactive Protein (CRP) is considered an objective (measurable) biomarker that is elevated when there is inflammation in tissues. CRP is used to direct antibiotic treatment. A goal of this study is to evaluate if CRP can be a marker for resolution of bacterial pneumonia in dogs. Clinicians will determine if CRP levels correlate with clinical and radiographic) x-ray) resolution of aspiration pneumonia.
Any dog with aspiration pneumonia may qualify for the study. Patients are treated as normal for aspiration pneumonia including lab tests, radiographs, antibiotic therapy, etc. Extra blood is taken for the special CRP testing. Patients return 7, 14 and 30 days after hospital discharge for rechecks. Clients complete several questionnaires regarding pet’s condition. There is no cost for the study follow-up exams.